The global plasma fractionation market size in 2026 is an important segment of the healthcare and pharmaceutical industry, supporting the production of essential plasma-derived medicines used across a broad range of therapeutic applications. Plasma fractionation is a method that separates human plasma into its individual proteins for therapeutic use. The process enables the production of immunoglobulins, albumin, coagulation factors, and protease inhibitors, which are used to address immune deficiencies, neurological disorders, bleeding conditions, metabolic deficiencies, critical care requirements, and other serious diseases.
According to Fortune Business Insights, the global plasma fractionation market size was valued at USD 40.27 billion in 2025 and is projected to grow from USD 43.55 billion in 2026 to USD 87.23 billion by 2034, exhibiting a CAGR of 9.1% during the forecast period. North America dominated the plasma fractionation market with a market share of 56.22% in 2025. The market is supported by increasing demand for plasma-derived medicines, rising diagnosis of immune and rare disorders, growing use of immunoglobulin therapies, and investments in plasma collection and fractionation capacity.
Plasma-derived products remain important for patients requiring long-term or emergency treatment. Immunoglobulins are widely used for immune deficiencies and autoimmune and neurological conditions, while albumin is used in critical care, trauma, burns, surgery, and liver-related conditions. Coagulation factors and other plasma proteins are also used in the treatment of bleeding and rare disorders. The market is also witnessing increasing attention toward plasma self-sufficiency. Governments and healthcare systems are working to reduce dependence on imported plasma-derived medicines by encouraging domestic plasma collection, manufacturing partnerships, and investments in fractionation facilities. These initiatives are expected to strengthen regional supply chains and improve access to essential therapies.
The increasing prevalence of immune deficiencies, autoimmune conditions, neurological disorders, and rare diseases is driving demand for plasma-derived medicines. Patients with primary immunodeficiency and other immune-compromised conditions may require recurring immunoglobulin replacement therapy, creating sustained demand for reliable plasma collection and fractionation capacity. Rising diagnosis rates and wider treatment availability are further supporting demand across hospitals, infusion centers, specialty clinics, and homecare settings.
A major restraint is the market’s dependence on human plasma donations. Plasma-derived medicines require a consistent supply of donated plasma, making production vulnerable to donor shortages, collection delays, regulatory restrictions, and regional supply limitations. Complex testing, purification, processing, and quality-release requirements can also affect product availability.
The expansion of plasma collection centers presents an important growth opportunity. Increasing demand for immunoglobulins, albumin, coagulation factors, and specialty plasma proteins is encouraging manufacturers to strengthen plasma supply networks. Expanding collection capacity can support higher fractionation output and improve the long-term availability of plasma-derived therapies.
The competitive landscape consists of major plasma-derived therapy manufacturers with capabilities spanning plasma collection, fractionation, purification, product development, and commercialization. Companies are focusing on product launches, label expansions, plasma collection expansion, manufacturing capacity investments, and regional supply partnerships.
CSL, Grifols, S.A., and Takeda Pharmaceutical Company Limited held a significant market position due to their broad product portfolios and established presence. Other companies are also strengthening their positions through developments in immunoglobulin products, coagulation factors, albumin, and specialty plasma-derived therapies. Product innovation is being observed across intravenous immunoglobulin, subcutaneous immunoglobulin, fibrinogen concentrates, prothrombin complex concentrates, and specialty immune globulins.
By Product (Albumin, Immunoglobulin {IVIG and SCIG}, Coagulation Factors {Factor IX, Factor VIII, and von Willebrand Factor}, and Protease Inhibitors {Alpha-1 Antitrypsin and C1 Esterase Inhibitor})
By Application (Immunology, Neurology, Hematology, Critical Care, and Pulmonology)
By End User (Hospitals & Clinics, Specialty Clinics & Infusion Centers, and Homecare Settings)
Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614